@article{a0e2b5e204ad4996bcb09573339b7d82,
title = "A Phase I Study of Oral CC-5013 (Lenalidomide, Revlimid{\texttrademark}), a Thalidomide Derivative, in Patients with Refractory Metastatic Cancer",
keywords = "Angiogenesis, Human vein endothelial cell proliferation, Pharmacokinetics",
author = "Tohnya, \{Tanyifor M.\} and Ng, \{Sylvia S.W.\} and Dahut, \{William L.\} and Wright, \{John J.\} and Arlen, \{Philip M.\} and Gulley, \{James L.\} and Catherine Parker and Jerome Zeldis and Figg, \{William D.\}",
note = "Funding Information: 1Clinical Pharmacology Research Core 2Medical Oncology Clinical Research Unit National Cancer Institute/National Institutes of Health, Bethesda, MD 3Celgene Corporation, Warren, NJ Funding Information: Address for correspondence: William D. Figg, Pharm D Clinical Pharmacology Research Unit National Cancer Institute, National Institutes of Health Bldg 10, Room 5A01 9000 Rockville Pike Bethesda, MD 20892 Fax: 301-402-8606 e-mail:
[email protected]",
year = "2004",
month = mar,
doi = "10.3816/CGC.2004.n.006",
language = "English",
volume = "2",
pages = "241--243",
journal = "Clinical Prostate Cancer",
issn = "1540-0352",
publisher = "Cancer Information Group, LP",
number = "4",
}